Hepatology International
https://doi.org/10.1007/s12072-022-10412-w

ORIGINAL ARTICLE

Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection

Minghui Li[1,2] · Fangfang Sun[1] · Xiaoyue Bi[1] · Yanjie Lin[2] · Liu Yang[1] · Tingting Jiang[1] · Wen Deng[1] · Yao Lu[1] · Lu Zhang[1] · Wei Yi[3] · Yao Xie[1,2]

Received: 3 June 2022 / Accepted: 13 August 2022

Abstract

Objective [illegible]

Methods [illegible]

Results [illegible] 28.1% (27/96), 23.7% (31/131), [illegible] 24.3% (9/37) [illegible] ($\chi^2 = 0.607$, $p = 0.738$). [illegible] 96.3% [illegible] 92.3% [illegible] 77.7%.

Conclusion [illegible]

[illegible]: NC 03214302.

Keywords [illegible]

Introduction

[illegible]

[illegible] 1215@163.com

[illegible] 00120184@[illegible]

1 [illegible] 100015, [illegible]

2 [illegible] 100015, [illegible]

3 [illegible] 100015, [illegible]

Published online: 15 September 2022

Patients and methods

Subjects and study design

HBsAg 0.05 250 IU/mL. HBsAg 250 IU/mL 500 500. HBsAg < 0.05 IU/mL HBsAg.

Statistical analysis

[illegible]

Results

Patient enrollment and deposition

A total 397 HBeAg- 30.74 3.85 112 (C) 251 106 96 24 232 168 24 131 37 6 (Fig. 1). HBeAg-

Changes of biochemical indexes and HBV DNA during pregnancy

HBV DNA 4 C (Table 1).

Changes of HBV DNA content during pregnancy and after delivery

A total 264 HBV DNA 96 (36.4%) C 168 (63.6%)

HBV DNA C HBV DNA 4 6 (Table 2). (Fig. 2),

Occurrence of postpartum hepatitis and treatment

A total 67 ALT 28.1% (27/96) C 23.8% (40/168) (Table 3). (p>0.1). 96.3% 92.3% 12 6 77.7% 12 12 (χ^2 = 2.876, p = 0.237) (Table 4).

5 ULN ALT < 10 ULN ALT 40 U/L) ALT ALT 10 ULN ALT [22]. ALT 7 (25.92%) 9 (29.03%) 1 (11.11%) (χ^2 = 1.190, p = 0.551). ALT 3 (11.11%) 2 (6.45%) 1 (11.11%) (χ^2 = 0.444, p = 0.801). 60 32



Fig. 1

DF 28 EG-IFN 9.99 0.22, A 10 10.00 0.00. 7 5 1 1 326 HB 41.4% (135) HB A > 0.05 I /m) a HB A 0.14 (0.08, 0.41) I /m. 96.3% (314) HB A (HB A > 1.0 /CO), HB A 64.46(18.15, 169.72) /CO. 98.5% HB (HB > 1.0 /CO). 98.5% (321) HBe (HBe > 1.0 /CO). HBV DNA 321 , 14.0% (HBV DNA 20 I /m), a HBV DNA 3.47 1.33 I /m.

HBV markers at birth and blocking e□ect of HBV mother-to-child transmission in newborns

A 346 189 157 , 50.07 1.07 3311.78 424.04 , A 9.97 0.26, A 5

Table 1 C l i . al . i c . _m al . a a_m . i . a c

	B . l i . l_m (31 32 . . a . i)				A . l_m (a . i . ial . a 4)				B . l i			
	C . l	a	T	p . al	C . l	a	T	p . al	C . l	a	T	p . al
A (a)	29.99. 3.60	31.35. 3.95	2.805	0.005	/	/	/	/	/	/	/	/
HB DNA (10 I /_mL)	7.99. 0.62	8.03. 0.51	0.676	0.500	7.55. 0.80	5.20. 0.72	9.910	< 0.001	7.87. 1.20	4.50. 1.03	23.928	< 0.001
HB A . i i , %	100%	100%			100%	100%			100%	100%		
AL (/L)	22.17. 14.80	23.46. 20.03	0.051	0.960	20.71. 27.69	23.75. 18.81	1.050	0.295	18.41. 11.80	20.30. 9.73	1.770	0.078
A (/L)	21.60. 14.61	22.44. 6.21	0.239	0.812	20.85. 13.03	23.63. 11.04	2.091	0.038	21.47. 9.22	22.72. 6.29	2.105	0.036
BIL (_m /L)	7.11. 2.41	7.74. 2.59	1.909	0.057	7.62. 3.44	7.99. 2.56	0.932	0.352	7.29. 2.68	7.48. 2.66	0.321	0.748
DBIL (_m /L)	1.72. 0.76	1.771.23	0.157	0.875	1.70. 1.03	1.91. 0.87	1.396	0.164	1.68. 1.26	1.72. 0.82	0.062	0.951
ALB (/L)	39.03. 3.28	37.09. 2.07	5.525	< 0.001	36.75. 2.44	36.24. 2.66	2.714	0.008	35.77. 2.86	35.86. 3.06	0.446	0.656
GG (/L)	10.15. 7.81	9.60. 6.73	0.957	0.339	9.79. 6.77	9.37. 5.61	0.997	0.320	10.06. 5.47	9.29. 4.86	0.273	0.786
AL (/L)	70.55. 34.25	76.80. 23.13	1.600	0.112	129.88. 52.41	149.66. 346.69	0.607	0.545	140.52. 32.73	159.07. 51.51	1.797	0.078
BA (_m /L)	3.25. 2.60	4.11. 8.91	0.531	0.596	3.70. 3.35	7.66. 41.40	0.902	0.368	8.90. 7.71	78.36. 536.73	1.155	0.253
B N (_m /L)	3.08. 0.78	3.96. 11.64	0.662	0.509	2.92. 0.62	3.10. 0.80	0.994	0.321	3.91. 3.35	3.64. 0.90	1.147	0.252
C (_m /L)	44.33. 5.78	45.63. 11.95	0.530	0.597	46.67. 5.19	50.90. 23.20	0.890	0.375	50.53. 8.63	55.51. 41.58	1.166	0.245
HO (_mm /L)	1.11. 0.10	1.18. 0.65	0.865	0.388	1.15. 0.13	1.13. 0.13	1.075	0.284	1.13. 0.15	1.10. 0.17	1.382	0.168
A (%)	109.99. 13.45	113.40. 10.34	2.089	0.041	116.68. 9.95	116.79. 10.59	0.102	0.919	117.03. 17.82	111.41. 15.73	2.732	0.007
IN	0.97. 0.05	1.35. 6.0((_mm2 1.726.	3.799	0	(0.607>3BDC21)	EMC(0.078)0DC3.96EMC0.78)	6.984	0	(3.96) / . a <</A a		()>>BDC()	EMC( ) / . a <</A

No es: HB DNA: . a . B . i . i . c . a c i ; HB A : . a . B a . i ; AL : a a . i a_mi . a ; A : a a a_mi . a ; B : . a . i . i ; DB : . i c . i . i ; ALB: A _mi ; GG : a_m a . i ; AL : a a i . . a ; BA: . a . a c i ; B N: a . i . ; C : c a . i . i ; HO : . . . ; A: . . . _m . i . im a c . i . i ; IN : . i a . i al . _ma i a . i

Table 2 HBV DNA [illegible]

HBV DNA [illegible] (l10 IU/mL)	[illegible]	[illegible]	[illegible]	T/p [illegible]	T/p [illegible]	T/p [illegible]
B[illegible]	7.99 0.62	8.05 0.51	7.98 0.52	0.708/0.479	0.077/0.939	0.648/0.518
4 [illegible]	7.55 0.80	5.24 0.62	5.21 0.94	11.226/ < 0.001	6.966/ < 0.001	0.207/0.837
B[illegible]	7.87 1.20	4.51 0.99	4.53 0.96	22.875/ < 0.001	15.275/ < 0.001	0.016/0.987
6 [illegible]	7.87 0.93	7.98 0.73	4.80 1.79	0.866/0.388	9.339/ < 0.001	10.212/ < 0.001
12 [illegible]	7.41 1.50	7.83 1.21	7.43 1.55	1.276/0.211	0.049/0.961	1.336/0.184
24 [illegible]	7.13 2.11	7.34 2.03	7.10 2.13	0.535/0.593	0.056/0.956	0.476/0.635

Notes: [illegible]

[illegible]

[illegible] 6 [illegible]



Fig. 2 [illegible] HBV DNA [illegible] HBV [illegible]

[illegible] HBV HBIG 100 IU [illegible] 10 [illegible] B [illegible] 6 [illegible] B [illegible] 1 [illegible] 6 [illegible] 262 [illegible] HBV [illegible] (155/156, 99.35%) [illegible] (96/106, 90.56%)(χ^2=12.132, $p < 0.001$).

Discussion

G[illegible] B [illegible] 5, 8 10, 23 [illegible] B [illegible]

Table 3 [illegible]

[illegible] (*n*)	C[illegible] (*n*=96)	Lmm[illegible] (*n*=131)	D[illegible] (*n*=37)	χ^2/p [illegible]	χ^2/p [illegible]	χ^2/p [illegible]	χ^2/p [illegible] C[illegible]
[illegible] %	28.1% (27)	23.7% (31)	24.3% (9)	0.580/0.446	0.195/0.658	0.007/0.934	0.601/0.438

N[illegible]: C[illegible]

Lmm[illegible]

D[illegible]

[illegible] HBV [illegible]

A [illegible] HBV. H[illegible], HBV [illegible] [20, 21, 24, 25]. C[illegible] HBV [20, 21, 24, 25]. [illegible] DF [illegible] DF [illegible] HBV [illegible] HBV [illegible]. M[illegible] DF [illegible] A[illegible] DF [illegible]. DF [illegible] HBV [illegible] HBV [illegible] [25, 26]. [illegible] HBV DNA [illegible] 10^6 IU/ml [illegible] HBV [illegible] [27–30]. [illegible] HBV [illegible] HBV DNA < 10^6 IU/ml [31]. A[illegible] HBV [illegible] m28 [illegible], DF [illegible] HBV DNA [illegible] 3 [illegible] (HBV DNA < 10^6 IU/ml) [illegible] 4 [illegible] [32]. [illegible] DF [illegible] 32 [illegible].

O[illegible] 32 [illegible] 99.35%, [illegible] C[illegible] (90.56%). A[illegible], HBV DNA





Acknowledgements

20. C [illegible] I [illegible] D [illegible] CMA, C [illegible] H [illegible] CMA. [illegible] B [illegible]). [illegible] G [illegible] B [illegible] 2019;2019(27):938 961
21. [illegible] NA, B [illegible] NH, C [illegible] KM, H [illegible] J, J [illegible] MM, M [illegible] MH, A [illegible] A [illegible] L [illegible] D. AA LD [illegible] B. H [illegible] 2016;63:261 283.
22. [illegible] HH, L [illegible] HF, C [illegible] C. C [illegible] B [illegible] (HB [illegible]) [illegible] H [illegible] I. 2008;2:370 375
23. C [illegible] J, L [illegible] L, H [illegible] H, [illegible] M, F [illegible] al. [illegible] B. F [illegible] M (L [illegible]). 2021;8: 796901
24. [illegible] K, K [illegible] M, L [illegible] GK, A [illegible], C [illegible] HL, C [illegible] CJ, [illegible] al. [illegible] B: [illegible] 2015 [illegible] H [illegible] I. 2016;10:1 98
25. E [illegible] A [illegible] L [illegible] E [illegible] E [illegible] A [illegible] L. EA L. C [illegible] G [illegible] B [illegible] J H [illegible] 2017;2017(67):370 398
26. [illegible] H. [illegible] B [illegible] G [illegible] B [illegible] 2016;24:881 884
27. L [illegible] FC, L [illegible] J, [illegible] J, C [illegible] J, [illegible] L, [illegible] al. [illegible] B [illegible] C [illegible] 2017;35:6627 6633
28. L [illegible] J, [illegible] B, C [illegible] C [illegible] J, F [illegible] J, [illegible] C, [illegible] al. [illegible] B [illegible] ? D [illegible] L [illegible] D [illegible] 2019;51:864 869
29. C [illegible] K [illegible] M [illegible] K [illegible] A [illegible] D, K [illegible] KO, [illegible] L,